RHHBY obtains FDA approval for Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.

A new breast cancer drug has received quick federal approval after a clinical trial showed it could more than double the time before a common type of breast cancer recurrence worsens.

H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Relay Therapeutics (RLAY – Research Report) today and set a price target ...

Barclays analyst Emily Field maintained a Hold rating on Roche Holding AG (RHHVF – Research Report) today and set a price target of ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

Trump and Harris Both Like a Child Tax Credit, but With Different Aims Kamala Harris’s campaign is pushing a version of the credit intended to fight child poverty, while Donald Trump sees the ...

Inside the dangerous world of Russian front-line soldiers working as double agents for the enemy ...

Daron Acemoglu, Simon Johnson and James Robinson won the 2024 Nobel economics prize "for studies of how institutions are formed and affect prosperity", the Royal Swedish Academy of Sciences said ...

Covering Netflix News Independently Since 2013. What’s on Netflix is not owned by or affiliated with Netflix or any of its partners in any capacity. The authors of this site also have no affiliation ...

Despite the odds, Trump has managed to fend off court cases, but his legal woes could follow him even after the election. In July, the case against Trump for hoarding documents in his Mar-a-Lago ...